UA75573C2 - C7 ester substituted taxanes, pharmaceutical composition based thereon (variants) and method for tumor growth inhibition - Google Patents

C7 ester substituted taxanes, pharmaceutical composition based thereon (variants) and method for tumor growth inhibition Download PDF

Info

Publication number
UA75573C2
UA75573C2 UA2001106734A UA2001106734A UA75573C2 UA 75573 C2 UA75573 C2 UA 75573C2 UA 2001106734 A UA2001106734 A UA 2001106734A UA 2001106734 A UA2001106734 A UA 2001106734A UA 75573 C2 UA75573 C2 UA 75573C2
Authority
UA
Ukraine
Prior art keywords
pyridyl
furyl
thienyl
alkyl
alkenyl
Prior art date
Application number
UA2001106734A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Univ Florida State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida State Res Found filed Critical Univ Florida State Res Found
Publication of UA75573C2 publication Critical patent/UA75573C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2001106734A 2000-02-02 2001-02-02 C7 ester substituted taxanes, pharmaceutical composition based thereon (variants) and method for tumor growth inhibition UA75573C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17979400P 2000-02-02 2000-02-02
PCT/US2001/003385 WO2001057027A1 (en) 2000-02-02 2001-02-02 C7 ester substituted taxanes as antitumor agents

Publications (1)

Publication Number Publication Date
UA75573C2 true UA75573C2 (en) 2006-05-15

Family

ID=22658029

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001106734A UA75573C2 (en) 2000-02-02 2001-02-02 C7 ester substituted taxanes, pharmaceutical composition based thereon (variants) and method for tumor growth inhibition

Country Status (35)

Country Link
US (3) US6610860B2 (enExample)
EP (1) EP1183253B8 (enExample)
JP (1) JP2003522167A (enExample)
KR (1) KR100784161B1 (enExample)
CN (1) CN1362955A (enExample)
AR (1) AR030188A1 (enExample)
AT (1) ATE396188T1 (enExample)
AU (1) AU776051B2 (enExample)
BG (1) BG65279B1 (enExample)
BR (1) BR0104749A (enExample)
CA (1) CA2368993C (enExample)
CO (1) CO5280224A1 (enExample)
CZ (1) CZ298484B6 (enExample)
DE (1) DE60134094D1 (enExample)
DK (1) DK1183253T3 (enExample)
ES (1) ES2307588T3 (enExample)
GE (1) GEP20043322B (enExample)
HK (1) HK1047938A1 (enExample)
HU (1) HUP0200917A3 (enExample)
IL (1) IL145641A0 (enExample)
MX (1) MXPA01009901A (enExample)
MY (1) MY137637A (enExample)
NO (1) NO327982B1 (enExample)
NZ (1) NZ514409A (enExample)
PL (1) PL202668B1 (enExample)
PT (1) PT1183253E (enExample)
RO (1) RO121777B1 (enExample)
RU (1) RU2265017C2 (enExample)
SA (1) SA01220045B1 (enExample)
SK (1) SK13712001A3 (enExample)
TR (1) TR200102856T1 (enExample)
TW (1) TWI291873B (enExample)
UA (1) UA75573C2 (enExample)
WO (1) WO2001057027A1 (enExample)
ZA (1) ZA200108060B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009900A (es) * 2000-02-02 2003-08-20 Univ Florida State Res Found Formulaciones de taxano que tienen solubilidad mejorada.
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
KR100819578B1 (ko) * 2001-08-01 2008-04-04 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 C7 에스테르 치환된 탁산
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
US20030082229A1 (en) * 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
US8012950B2 (en) * 2003-08-29 2011-09-06 Wisconsin Alumni Research Foundation Method to diagnose and treat degenerative joint disease
ES2295937T3 (es) 2003-09-25 2008-04-16 Tapestry Pharmaceuticals, Inc. Analogos de 9,10-alfa,alfa-oh-taxano y procedimientos para su produccion.
SI1664033T1 (sl) * 2003-09-25 2008-04-30 Tapestry Pharmaceuticals Inc Analogi 9,10-alfa,alfa-oh-taksana in postopki za proizvodnjo le-teh
CN1960721A (zh) * 2004-03-05 2007-05-09 佛罗里达州立大学研究基金有限公司 C7乳酰氧基取代的紫杉烷类
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
AU2005294214A1 (en) * 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
US8232262B2 (en) 2004-10-25 2012-07-31 Dekk-Tec, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor Agents
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP2118079A1 (en) 2007-02-07 2009-11-18 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Synthetic macrocyclic compounds for treating cancer
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
KR101505415B1 (ko) 2007-04-06 2015-03-25 지오팜 온콜로지 인코포레이티드 이소포스포르아미드 머스타드의 염 및 이의 동족체
SG183657A1 (en) 2008-07-31 2012-09-27 Ziopharm Oncology Inc Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
EP2401285B1 (en) 2009-02-24 2012-10-10 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
BR112012022552A8 (pt) 2010-03-10 2017-12-05 Stanford Res Inst Int uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
CA2841120C (en) 2011-07-11 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-ir700 conjugates for photodynamic therapy
US20150157580A1 (en) 2012-05-25 2015-06-11 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
AU2014331667B2 (en) 2013-10-11 2019-08-22 Biomed Valley Discoveries, Inc. TEM8 antibodies and their use
WO2016022896A1 (en) 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Photo-controlled removal of targets in vitro and in vivo
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
AU2019253681A1 (en) 2018-04-10 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
EA202290208A1 (ru) 2019-07-02 2022-03-25 Дзе Юнайтед Стейтс Оф Эмерика, Эз Репрезентед Бай Дзе Секретэри, Дипартмент Оф Хелт Энд Хьюман Сервисиз МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
EP4247410A4 (en) 2020-11-19 2025-05-07 KaliVir Immunotherapeutics, Inc. ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL
EP4284439A1 (en) 2021-01-29 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
PE20250454A1 (es) 2021-04-30 2025-02-19 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc
EP4547274A1 (en) 2022-06-30 2025-05-07 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd25-specific antibodies and uses thereof
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
SE463189B (sv) 1989-03-13 1990-10-22 Eston Joensson Preparat avsett att tillfoeras amalgamfyllningar i taender foer att daerigenom hindra eller minska avgaang av kvicksilver eller kvicksilveraanga
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5489601A (en) * 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5350866A (en) 1991-09-23 1994-09-27 Bristol-Myers Squibb Company 10-desacetoxytaxol derivatives
US5243045A (en) 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5714513A (en) 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
PT1001036E (pt) 1992-01-15 2005-01-31 Squibb & Sons Inc Processos enzimaticos para o desdobramento de misturas enantiomericas de compostos uteis como intermediarios na preparacao de taxanos
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
ES2134847T3 (es) 1992-04-17 1999-10-16 Abbott Lab Derivados de taxol.
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5319112A (en) 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
EP1251127B1 (en) 1992-12-23 2005-11-09 Bristol-Myers Squibb Company Novel sidechain-bearing taxanes and intermediates thereof
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
PT690712E (pt) * 1993-03-22 2002-05-31 Univ Florida State Taxanos possuindo uma cadeia lateral substituida com piridilo
IL109051A0 (en) * 1993-03-22 1994-06-24 Univ Florida State Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
PT690867E (pt) * 1993-03-22 2003-06-30 Univ Florida State Taxanos possuindo uma cadeia lateral substituida com furilo ou tienilo
CA2161328A1 (en) 1993-06-11 1994-12-22 Robert C. Kelly Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
IL109926A (en) 1993-06-15 2000-02-29 Bristol Myers Squibb Co Methods for the preparation of taxanes and microorganisms and enzymes utilized therein
TW397866B (en) 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
FR2711369B1 (fr) 1993-10-20 1995-11-17 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions qui les contiennent.
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5414869A (en) * 1993-11-26 1995-05-16 Thomson; Margaret I. Knotless scarf and method of making same
FR2721024B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO1996013495A1 (en) * 1994-10-28 1996-05-09 The Research Foundation Of State University Of New York Taxoid derivatives, their preparation and their use as antitumor agents
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
CA2231837A1 (en) 1995-09-13 1997-03-20 Florida State University Radiosensitizing taxanes and their pharmaceutical preparations
US5767297A (en) 1997-02-05 1998-06-16 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997042181A1 (en) 1996-05-06 1997-11-13 Florida State University 1-deoxy baccatin iii, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
WO1997044027A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
AU741433B2 (en) * 1997-10-08 2001-11-29 Bio Research Corporation Of Yokohama Taxoid derivatives and process for producing the same
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
US5964739A (en) * 1998-06-18 1999-10-12 Champ; Raynido A. Safety disposable needle structure
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
EP1192126A1 (en) 1999-06-21 2002-04-03 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-n-acyl(2r,3s)-3-phenylisoserine activated esters and methods for production thereof
US6348215B1 (en) * 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
CO5280224A1 (es) * 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
MXPA01009900A (es) * 2000-02-02 2003-08-20 Univ Florida State Res Found Formulaciones de taxano que tienen solubilidad mejorada.
HUP0200995A3 (en) 2000-02-02 2005-02-28 Univ Florida State Res Found Taxane formulations having improved solubility
IT1319168B1 (it) 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.

Also Published As

Publication number Publication date
PL350026A1 (en) 2002-10-21
HUP0200917A2 (en) 2002-08-28
SA01220045B1 (ar) 2008-06-07
CN1362955A (zh) 2002-08-07
US20020013346A1 (en) 2002-01-31
NZ514409A (en) 2004-03-26
US20040014979A1 (en) 2004-01-22
HK1047938A1 (zh) 2003-03-14
CZ298484B6 (cs) 2007-10-17
KR20010111583A (ko) 2001-12-19
AU3323901A (en) 2001-08-14
ES2307588T3 (es) 2008-12-01
EP1183253B8 (en) 2009-01-07
AR030188A1 (es) 2003-08-13
JP2003522167A (ja) 2003-07-22
DK1183253T3 (da) 2008-09-22
TR200102856T1 (tr) 2002-06-21
WO2001057027A1 (en) 2001-08-09
CA2368993A1 (en) 2001-08-09
DE60134094D1 (de) 2008-07-03
MY137637A (en) 2009-02-27
MXPA01009901A (es) 2003-07-28
TWI291873B (en) 2008-01-01
AU776051B2 (en) 2004-08-26
EP1183253A1 (en) 2002-03-06
EP1183253B1 (en) 2008-05-21
BG105967A (en) 2002-08-30
IL145641A0 (en) 2002-06-30
SK13712001A3 (sk) 2002-05-09
CO5280224A1 (es) 2003-05-30
BR0104749A (pt) 2001-12-26
US20070249708A1 (en) 2007-10-25
NO20014759L (no) 2001-11-29
US7186849B2 (en) 2007-03-06
NO327982B1 (no) 2009-11-02
NO20014759D0 (no) 2001-10-01
PT1183253E (pt) 2008-08-04
US6610860B2 (en) 2003-08-26
ZA200108060B (en) 2003-12-01
BG65279B1 (bg) 2007-11-30
RO121777B1 (ro) 2008-04-30
HUP0200917A3 (en) 2004-07-28
GEP20043322B (en) 2003-12-10
HU0200917D0 (en) 2002-04-29
PL202668B1 (pl) 2009-07-31
CZ20013503A3 (cs) 2002-03-13
RU2265017C2 (ru) 2005-11-27
CA2368993C (en) 2009-10-20
ATE396188T1 (de) 2008-06-15
KR100784161B1 (ko) 2007-12-12

Similar Documents

Publication Publication Date Title
UA75573C2 (en) C7 ester substituted taxanes, pharmaceutical composition based thereon (variants) and method for tumor growth inhibition
KR20010111580A (ko) 개선된 용해도를 갖는 탁산 제형물
RU2264400C2 (ru) Таксан, фармацевтическая композиция на его основе и способ ингибирования роста опухоли
RU2265019C2 (ru) Таксаны, фармацевтические композиции, способы ингибирования
HK1047935A1 (zh) 作为抗肿瘤剂的c7杂取代乙酸酯取代的紫杉烷
UA75039C2 (en) Taxanes having an ester substituent at c10, pharmaceutical composition based thereon and a method for inhibiting tumors growth
KR101169818B1 (ko) C10에서 시클로펜틸 에스테르로 치환된 탁산
US7160919B2 (en) C7 lactyloxy-substituted taxanes
KR100819578B1 (ko) C7 에스테르 치환된 탁산